[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"safety-after-oral-intake\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:safety-after-oral-intake":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100609301","phase-4-effects-of-energy-drinks-on-cardiovascular-endpoints-100609301",false,"NCT07212803","Effects of Energy Drinks on Cardiovascular Endpoints","Evaluation of Energy Drinks on Electrocardiographic Parameters: A Randomized, Double Blind, Controlled, Crossover, Proof-of-concept Study","Inclusion Criteria:\n\n* Healthy male or female adults 18-40 years of age\n* Female participants of child-bearing potential must have a negative pregnancy test at the baseline visit\n* Participants must be willing to refrain from caffeine and alcohol use 72 hours prior to sessions on study days\n* Participants must be willing and able to: (1.) Consume up to 1 liter of fluid within a 30-minute period per visit (2.) Swallow a single large capsule per visit\n* Participants must be willing to fast 10 hours prior to sessions on study days (only water is allowed during the fasting and active study period)\n* Participants must have active health insurance throughout the duration of the study\n\nExclusion Criteria:\n\n* Have a corrected QT (QTc) interval greater than 450 milliseconds (ms) for males or greater than 470 milliseconds (ms) for females, determined during the baseline visit\n* Presence of any known medical condition, confirmed through participant interview. Examples of these include but not limited to: Dyslipidemia, Thyroid disease, Diabetes, Recurrent headache, Any psychiatric condition or neurological disorder, History of alcohol or drug abuse, Past diagnosis or history of renal insufficiencies, Hepatic dysfunction, Electrolyte imbalances requiring hospitalization\n* Presence of any known heart\u002Fcardiac diseases or conditions such as: Atrial Fibrillation, History of stroke or heart attack, Hypertension, Heart Failure, Vascular Disease, Family history\u002FActive Long QT Syndrome, Coronary artery disease, Cardiomyopathy, Valvular heart disease, Ventricular arrhythmia, Congenital heart defect, Pericardial disease, Myocarditis\n* Study physician recommendation for participant to not be enrolled.\n* Are underweight (BMI\\\u003C18.5 kg\u002Fm2, CDC 2024), have poor eating habits resulting in poor weight control, or have any factors that will put the participant at risk from fasting.\n* Have any contraindications to the use of moxifloxacin, including a past medical history of myasthenia gravis, QT prolongation, or hypersensitivities and allergic reactions to moxifloxacin or any other fluoroquinolone antibiotics\n* Pre-existing risk to tendinitis and tendon rupture, peripheral neuropathy, or central nervous system side effects\n* Concurrent use of ANY medication taken daily including herbal products or supplements (daily basis is defined as greater than 2 days per week)\n* Self-reported allergy to taurine\n* Self-reported allergy to nuts (peanuts, pecans, cashews, etc.)\n* Self-reported allergic reaction to the adhesive pads (electrodes, continuous glucose monitors, etc.)\n* Fear of needle puncture\n* Smokers using cigarettes, vaporized nicotine, or marijuana products currently or within the past month\n* Current usage of any nicotine or tobacco products including but not limited to intranasal, sublingual, oral, or transdermal dosage forms\n* Currently pregnant or breastfeeding\n* Have a positive pregnancy test during the baseline visit\n* Are currently enrolled in any other clinical study or have participated in another study within the last 30 days\n* Non-English speaking\u002Freading individuals will be excluded due to the unavailability of medically qualified translators throughout all study procedures\n* If the candidate does not sign the informed consent document",true,"ALL","18 Years","40 Years",{"count":21,"type":22},3,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","This is a clinical trial looking at the impact of energy drinks on heart related parameters. The study will enroll 3 participants who will be exposed to 8 different interventions.",[28,29],"Healthy Volunteers","Safety After Oral Intake",[31],"Energy Drinks","RECRUITING","2025-11-20",{"date":35,"type":36},"2025-11-26","ACTUAL",{"date":38,"type":36},"2025-11-01",{"date":40,"type":22},"2026-09",{"name":42,"class":43},"University of the Pacific","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":44},"100603710","phase-1-a-research-study-to-evaluate-blx-7006-in-healthy-adults-100603710","NCT07140055","A Research Study to Evaluate BLX-7006 in Healthy Adults","A Phase 1 Randomized, Double-blind, Placebo-controlled Single-ascending Dose and Multiple-ascending Dose (SAD and MAD) Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Novel Glucagon-like Peptide-1 Receptor Agonist (GLP-1RA) BLX-7006 in Healthy Adults With a Body Mass Index (BMI) of 20 - 35 kg\u002Fm2","Inclusion Criteria:\n\n* Healthy males or females, 18-65 years, BMI 20-35 kilograms\u002Fmeter² (kg\u002Fm²), weight ≥50 kilograms (kg).\n* Normal or clinically acceptable labs, vital signs\n* HbA1c \\\u003C6.5%, non-fasting glucose 4.0-7.8 milimol\u002FLiter (mmol\u002FL)\n* Willing to follow contraception requirements, avoid alcohol, nicotine, and blood donation per protocol, and comply with all study visits and procedures.\n\nExclusion Criteria:\n\n* History of diabetes, clinically significant cardiovascular, hepatic, renal, gastrointestinal, psychiatric, or neurologic disease, or abnormal labs\u002FEchocardiograms (ECG) deemed clinically relevant.\n* Prior gastrointestinal (GI) surgery affecting absorption (e.g., gastric bypass) or chronic GI disorders.\n* History or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 (MEN2); malignancy within 5 years (except treated basal cell or in situ cervical cancer).\n* History of severe allergic reactions, seizures, or psychiatric hospitalization; positive drug, alcohol, or cotinine test.\n* Use of prescription drugs, Over the counter (OTC) \u002Fherbal supplements\n* Participation in another clinical trial or blood donation within 30 days (or 5 half-lives of prior drug).\n* Any condition or history that may compromise safety, study conduct, or compliance, in the opinion of the Investigator.","65 Years",{"count":54,"type":22},76,[56],"PHASE1","This study will test an oral medicine called BLX-7006, which acts like the hormone Glucagon-like Peptide-1 (GLP-1) to help control blood sugar and body weight. Current GLP-1 medicines are given by injection. This study will see if BLX-7006 is safe, how the body processes it, and whether food changes how it is absorbed. The main goal is to see if BLX-7006 is safe and well tolerated. Secondary objectives of the study will measure how BLX-7006 moves through the body after an oral dose, including how quickly it is absorbed, how long it stays in the blood, and how the body removes it. It will also look at how the drug affects the body by looking at markers of glucose metabolism.",[59,29],"Normal Healthy Volunteer",[61,62,63,59],"Obesity","Type 2 Diabetes","Metabolic Disorders","NOT_YET_RECRUITING","2025-08-22",{"date":67,"type":36},"2025-08-24",{"date":69,"type":22},"2025-09",{"date":71,"type":22},"2026-05",{"name":73,"class":74},"Biolexis Therapeutics","INDUSTRY"]